abs151.txt	background		surgical	resection	provides	the	only	potentially	curative	treatmentof	pancreatic	cancer		neoadjuvant	chemotherapy	and/or	radiation	(nat)	is	used	todownstage	patients	with	borderline	resectable	tumors		the	objective	of	this	studywas	to	examine	the	postoperative	morbidity	and	mortality	of	nat	afterpancreaticoduodenectomy	(pd)	for	pancreatic	ductal	adenocarcinoma	(pda)	methods		using	the	american	college	of	surgeons-national	surgical	qualityimprovement	project	targeted	pancreatectomy	data		we	identified	patients	whounderwent	a	pd	for	pda	from	2014	to	2015		patients	were	grouped	by	receipt	of	nat90	days	before	pd		bivariable	and	multivariable	analyses	was	used	to	comparepostoperative	outcomes	results		a	total	of	3748	patients	with	pda	underwent	pd		926	(24	7%)	receivednat		those	in	the	nat	group	had	more	major	vein	resections		and	longer	operatingtimes	(all	p	<	0	001)		on	pathologic	staging		those	in	the	nat	group	had	smallertumors	(t1		10	9%	vs	5	1%		p	<	0	001)	and	fewer	nodes	positive	(n0		49%	vs	28%	p	<	0	001)		there	were	no	differences	in	30-day	postoperative	mortality	oroverall	complications		on	multivariable	analysis		patients	who	received	nat	had	alower	likelihood	of	pancreatic	fistula	(or		0	67		p	<	0	001)	conclusion		nat	does	not	increase	the	overall	postoperative	morbidity	ormortality	of	pd	for	pda		there	is	a	decreased	likelihood	of	pancreatic	fistulasin	patients	that	receive	neoadjuvant	therapy	
